Quick Answer
TriSalus Life Sciences, Inc. reported Total Revenue of $45.15 million for fiscal year 2025.
TriSalus Life Sciences, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $45.15M +53.4% |
$29.43M +59.0% |
$18.51M +49.3% |
$12.40M | — | — |
| Revenue (ASC 606) | $45.15M +53.4% |
$29.43M +59.0% |
$18.51M +49.3% |
$12.40M | — | — |
| Net Income | -$39.23M -30.6% |
-$30.05M +49.4% |
-$59.36M -25.8% |
-$47.19M -1089.8% |
$4.77M | — |
| Diluted EPS | -$1.84 -40.5% |
-$1.31 +80.6% |
-$6.77 +95.8% |
-$161.55 | — | — |
| Total Assets | $35.33M +47.4% |
$23.97M -2.5% |
$24.60M +11.8% |
$22.00M -91.2% |
$250.53M -0.6% |
$252.01M |
| Cash and Equivalents | $20.44M +139.8% |
$8.53M -27.6% |
$11.78M +25.1% |
$9.41M +4586.3% |
$200.9K -85.0% |
$1.33M |
| Long-Term Debt | $33.05M +49.6% |
$22.08M | $0.00 | — | — | — |
| Stockholders Equity | -$33.86M -30.8% |
-$25.89M +4.3% |
-$27.07M +84.7% |
-$177.13M -36.7% |
-$129.60M | $0.00 |
| R&D Expense | $14.96M -15.4% |
$17.69M -40.7% |
$29.84M +39.7% |
$21.36M | — | — |
| Operating Income | -$26.95M +25.5% |
-$36.16M +33.6% |
-$54.48M -49.5% |
-$36.44M -1098.4% |
-$3.04M | — |
| Gross Profit | $38.19M +50.8% |
$25.33M +59.2% |
$15.91M +56.9% |
$10.14M | — | — |
| Shares Outstanding | 50.00M +59.8% |
31.28M +18.9% |
26.32M +7463.9% |
347,926 | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $11.57M | +57.4% | +3.1% |
| Revenue (ASC 606) | September 30, 2025 | $11.57M | +57.4% | +3.1% |
| Net Income | September 30, 2025 | -$10.81M | -350.6% | -30.4% |
| Diluted EPS | September 30, 2025 | -$0.96 | -700.0% | -255.6% |
| Total Assets | September 30, 2025 | $36.46M | +32.7% | -11.7% |
| Cash and Equivalents | September 30, 2025 | $22.69M | +101.0% | -14.4% |
| Long-Term Debt | September 30, 2025 | $32.76M | +51.1% | +1.5% |
| Stockholders Equity | September 30, 2025 | -$26.73M | -30.8% | -37.6% |
| R&D Expense | September 30, 2025 | $5.18M | +22.7% | +31.9% |
| Operating Income | September 30, 2025 | -$9.01M | -3.1% | -22.9% |
| Gross Profit | September 30, 2025 | $9.66M | +52.2% | +2.6% |
| Shares Outstanding | September 30, 2025 | 49.89M | +63.7% | +31.4% |
- TriSalus Life Sciences, Inc. reported Total Revenue of $45.15 million for fiscal year 2025.
- TriSalus Life Sciences, Inc. showed an increase of +53.4% in Total Revenue compared to the prior fiscal year.
- TriSalus Life Sciences, Inc. reported Revenue (ASC 606) of $45.15 million for fiscal year 2025.
- TriSalus Life Sciences, Inc. showed an increase of +53.4% in Revenue (ASC 606) compared to the prior fiscal year.
- TriSalus Life Sciences, Inc. reported Net Income of -$39.23 million for fiscal year 2025.
- TriSalus Life Sciences, Inc. showed a decrease of -30.6% in Net Income compared to the prior fiscal year.
- TriSalus Life Sciences, Inc. reported Diluted EPS of $1.84 per share (loss) for fiscal year 2025.
- TriSalus Life Sciences, Inc. showed a decrease of -40.5% in Diluted EPS compared to the prior fiscal year.
- TriSalus Life Sciences, Inc. reported Total Assets of $35.33 million for fiscal year 2025.
- TriSalus Life Sciences, Inc. showed an increase of +47.4% in Total Assets compared to the prior fiscal year.
- TriSalus Life Sciences, Inc. reported Cash and Equivalents of $20.44 million for fiscal year 2025.
- TriSalus Life Sciences, Inc. showed an increase of +139.8% in Cash and Equivalents compared to the prior fiscal year.
- TriSalus Life Sciences, Inc. reported Long-Term Debt of $33.05 million for fiscal year 2025.
- TriSalus Life Sciences, Inc. showed an increase of +49.6% in Long-Term Debt compared to the prior fiscal year.
- TriSalus Life Sciences, Inc. reported Stockholders Equity of -$33.86 million for fiscal year 2025.
- TriSalus Life Sciences, Inc. showed a decrease of -30.8% in Stockholders Equity compared to the prior fiscal year.
- TriSalus Life Sciences, Inc. reported R&D Expense of $14.96 million for fiscal year 2025.
- TriSalus Life Sciences, Inc. showed a decrease of -15.4% in R&D Expense compared to the prior fiscal year.
- TriSalus Life Sciences, Inc. reported Operating Income of -$26.95 million for fiscal year 2025.
- TriSalus Life Sciences, Inc. showed an increase of +25.5% in Operating Income compared to the prior fiscal year.
- TriSalus Life Sciences, Inc. reported Gross Profit of $38.19 million for fiscal year 2025.
- TriSalus Life Sciences, Inc. showed an increase of +50.8% in Gross Profit compared to the prior fiscal year.
- TriSalus Life Sciences, Inc. reported Shares Outstanding of 50.00 million shares for fiscal year 2025.
- TriSalus Life Sciences, Inc. showed an increase of +59.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: